Who owns Insmed?

Who owns Insmed?

As a result of the transaction, Merck purchased all rights to Insmed’s follow-on biologic assets, including INS-19 and INS-20, as well as control of the Boulder, Colorado-based manufacturing facility. Merck, through an affiliate, has assumed the facility’s lease and ownership of all the equipment in the building.

Is Insmed a good company?

Insmed has an overall rating of 3.9 out of 5, based on over 40 reviews left anonymously by employees. 76% of employees would recommend working at Insmed to a friend and 78% have a positive outlook for the business. This rating has improved by 3% over the last 12 months.

How many employees does Insmed have?

600 employees
Our commitment to patients has no borders. In addition to our global corporate headquarters in Bridgewater, NJ, we have offices throughout Europe and in Japan, with more than 600 employees who are dedicated to serving the needs of patients and their families.

What kind of company is insmed?

biopharmaceutical company
Description. Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.

What kind of company is Insmed?

What is Insmed?

Insmed is founded as a private company by Dr. Joseph Larner in Charlottesville, Va., to develop medicines to treat diabetes. An installation at Insmed’s global headquarters honors the Company’s past as we look toward the future.

Is Insmed a registered trademark of Insmed incorporated?

Insmed, ARIKAYCE, Arikares, and PULMOVANCE are trademarks of Insmed Incorporated. All other trademarks are property of their respective owner.

Are all pages included in the Insmed website?

All pages Includes unmodified extension pages. Insmed (INSM) is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases.

What did Insmed get in the AstraZeneca deal?

Insmed enters into a worldwide license agreement with AstraZeneca for a product candidate, expanding the company’s rare disease pipeline. Insmed receives Orphan Drug Designation, Qualified Infectious Disease Product designation, and Fast Track status for its lead product candidate.